Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China.
Cancer Biol Med. 2021 Feb 15;18(1):34-51. doi: 10.20892/j.issn.2095-3941.2020.0216.
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of skin-homing non-Hodgkin lymphomas. There are limited options for effective treatment of patients with advanced-stage CTCL, leading to a poor survival rate. Epigenetics plays a pivotal role in regulating gene expression without altering the DNA sequence. Epigenetic alterations are involved in virtually all key cancer-associated pathways and are fundamental to the genesis of cancer. In recent years, the epigenetic hallmarks of CTCL have been gradually elucidated and their potential values in the diagnosis, prognosis, and therapeutic intervention have been clarified. In this review, we summarize the current knowledge of the best-studied epigenetic modifications in CTCL, including DNA methylation, histone modifications, microRNAs, and chromatin remodelers. These epigenetic regulators are essential in the development of CTCL and provide new insights into the clinical treatments of this refractory disease.
皮肤 T 细胞淋巴瘤（cutaneous T-cell lymphomas，CTCL）是一组异质性的皮肤归巢非霍奇金淋巴瘤。对于晚期 CTCL 患者，有效的治疗选择有限，导致生存率较差。表观遗传学在不改变 DNA 序列的情况下调节基因表达中起着关键作用。表观遗传改变几乎涉及所有关键的癌症相关途径，是癌症发生的基础。近年来，CTCL 的表观遗传特征逐渐被阐明，其在诊断、预后和治疗干预中的潜在价值也得到了阐明。在这篇综述中，我们总结了 CTCL 中研究最充分的表观遗传修饰的最新知识，包括 DNA 甲基化、组蛋白修饰、microRNAs 和染色质重塑因子。这些表观遗传调节剂在 CTCL 的发展中至关重要，并为这种难治性疾病的临床治疗提供了新的见解。
